Because the initial design goals of the HDL mimetic peptide therapeutic program have now been met, the company will now move rapidly to validate other key cardio-protective characteristics of LSI-518P and begin conducting a comprehensive series of toxicology studies in the next phase of the LSI-518P development program supportive of an IND filing and initiation of Phase I trials.
Bryan Brewer, chief scientific director of Lipid Sciences, said: “This study confirms, in a well-accepted animal model, that LSI-518P is highly effective in reducing the build-up of atherosclerotic plaque in the arterial wall.”